Bank of New York Mellon Corp Acquires 25,199 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO)

Bank of New York Mellon Corp grew its stake in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 31.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 104,966 shares of the company’s stock after acquiring an additional 25,199 shares during the period. Bank of New York Mellon Corp owned 0.20% of ALX Oncology worth $633,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. CANADA LIFE ASSURANCE Co acquired a new position in ALX Oncology in the first quarter valued at about $27,000. EntryPoint Capital LLC acquired a new position in ALX Oncology in the 1st quarter valued at approximately $32,000. China Universal Asset Management Co. Ltd. raised its position in ALX Oncology by 66.4% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 9,587 shares of the company’s stock worth $107,000 after purchasing an additional 3,825 shares during the last quarter. Dynamic Technology Lab Private Ltd acquired a new position in shares of ALX Oncology in the fourth quarter worth approximately $215,000. Finally, California State Teachers Retirement System boosted its stake in shares of ALX Oncology by 413.8% in the 1st quarter. California State Teachers Retirement System now owns 22,797 shares of the company’s stock valued at $254,000 after purchasing an additional 18,360 shares during the last quarter. Institutional investors own 97.97% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on ALXO. UBS Group decreased their target price on ALX Oncology from $25.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, August 16th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a research report on Monday, August 12th. Stifel Nicolaus reiterated a “hold” rating and set a $3.00 target price (down previously from $5.00) on shares of ALX Oncology in a research report on Friday, August 9th. Lifesci Capital lowered ALX Oncology from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, July 31st. Finally, HC Wainwright reiterated a “buy” rating and issued a $25.00 target price on shares of ALX Oncology in a research note on Tuesday, August 13th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $14.00.

Insiders Place Their Bets

In other ALX Oncology news, insider Jaume Pons sold 20,000 shares of ALX Oncology stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $7.90, for a total transaction of $158,000.00. Following the completion of the transaction, the insider now owns 593,447 shares in the company, valued at $4,688,231.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In the last quarter, insiders have sold 28,398 shares of company stock worth $200,043. Company insiders own 33.40% of the company’s stock.

ALX Oncology Price Performance

Shares of ALX Oncology stock opened at $1.99 on Tuesday. The company has a fifty day moving average of $3.33 and a 200-day moving average of $8.60. The company has a debt-to-equity ratio of 0.06, a quick ratio of 4.39 and a current ratio of 4.39. ALX Oncology Holdings Inc. has a 52-week low of $1.88 and a 52-week high of $17.83. The stock has a market capitalization of $103.68 million, a price-to-earnings ratio of -0.53 and a beta of 1.01.

ALX Oncology (NASDAQ:ALXO) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.01. Equities research analysts expect that ALX Oncology Holdings Inc. will post -3.04 EPS for the current year.

ALX Oncology Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.